ماپروتیلین

Key facts

Drug.Verifiedfields

changed

Drug.Watchedfields

changed

Drug.verifiedrevid

477169275

Drug.IUPAC_name

N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine

Drug.image

Maprotiline structure.svg

Drug.image_class

skin-invert-image

Drug.width

200px

Drug.image2

Maprotiline ball-and-stick model.png

Drug.image_class2

bg-transparent

Drug.width2

200px

Drug.tradename

Ludiomil, others

Drug.MedlinePlus

a682158

Drug.pregnancy_US_comment

B3[in US?]

Drug.legal_AU

S4

Drug.legal_BR

C1

Drug.legal_US

Rx-only

Drug.routes_of_administration

Oral, intramuscular, intravenous

Drug.bioavailability

66–70%

via Wikipedia infobox

Chemical data

Formula

C20H23N

Molecular weight

277.4 g/mol

IUPAC name

N-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine

SMILES

CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24

InChIKey

QSLMDECMDJKHMQ-UHFFFAOYSA-N

XLogP

4.6

Polar surface area

12 Ų

H-bond donors

1

H-bond acceptors

1

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Approved

Molecule type

Small molecule

First approval

1980

Admin. routes

oral

Indications

anxiety, Dementia, glioblastoma multiforme, depressive disorder

via ChEMBL · EBI

• Maprotiline.Modern problems of pharmacopsychiatry · 1982
• Maprotiline-induced ataxia.Journal of clinical psychopharmacology · 1986
• Maprotiline Ameliorates High Glucose-Induced Dysfunction in Renal Glomerular Endothelial Cells.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2022
• Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states.Drugs · 1977
• Maprotiline-induced myoclonus.Journal of clinical psychopharmacology · 1983

via PubMed

Wikidata facts

Subclass of

chemical compound

Mass

277.18305

Has use

medication

via Wikidata · CC0